ArticleCancer immunology, immunotherapy : CII2026

A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies.

Piotr Rutkowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.